Brian Au
Podiatrist · Orange, CANPI 1508392572
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,747 of the $10,749 with a category attached, or 72.1%. 18 manufacturers reported payments, led by Stryker at 36.7% of the total. Reporting peaked in 2021 at $4,986 and has fallen 86.6% since, to $668 in 2025. Among podiatrist clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 145 payments — averaging $74.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$4K
- Arthrex$3K
- Biotissue Holdings Inc.$778
- Smith+Nephew$503
- Paragon 28, Inc.$467
- Linvatec Corporation$400
- plus $2K from 12 others
What the payments were for
- Travel & lodging$6036%
- Food & beverage$7,74772%
- Education$2,40022%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 89 | $3,945 |
| Arthrex | 12 | $3,118 |
| Biotissue Holdings Inc. | 6 | $778 |
| Smith+Nephew | 9 | $503 |
| Paragon 28, Inc. | 4 | $467 |
| Linvatec Corporation | 3 | $400 |
| Integra Lifesciences Corporation | 6 | $378 |
| In2bones USA, LLC | 3 | $345 |
| Ossio Inc | 2 | $204 |
| Acera Surgical, Inc. | 2 | $182 |
| Averitas Pharma Inc. | 2 | $120 |
| AMDT Holdings, Inc. | 1 | $80 |
| Conmed Corporation | 1 | $56 |
| Johnson & Johnson | 1 | $45 |
| Saxum Surgical, Inc. | 1 | $44 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $32 |
| Krystal Biotech Inc | 1 | $30 |
| Bard Peripheral Vascular, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTEGRA$851
- NEOX$778
- CLARIX$778
- PROSTEP MICA$530
- AUGMENT INJECTABLE$296
- INTEGRA DERMAL REGENERATION TEMPLATE$284
- PRIMATRIX$284
- Taylor Spatial Frame$274
- Portfolio$262
- ALLOMATRIX$171
- ORTHOLOC 2 LAPIFUSE$170
- BioBrace 23mm$151
- AFFINITI EH$149
- Reference Toe System$146
- CoLink$146
- Restrata Wound Matrix$135
- HOFFMANN$132
- Quantum Total Ankle$132
- Additive Orthopedics$120
- PROPHECY$112
How this compares
$10,749 in reported general payments places this provider in the 90th percentile of 721 podiatrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 18 | $7,005 |
| Diclofenac Sodium | 88 | $3,852 |
| Ketoconazole | 104 | $2,438 |
| Ciclopirox | 116 | $2,071 |
| Clotrimazole | 36 | $624 |
| Ammonium Lactate | 32 | $619 |
| Terbinafine Hcl | 25 | $405 |
| Doxycycline Hyclate | 69 | $392 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 28 | $383 |
| Mupirocin | 29 | $161 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 30 | $158 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 18 | $133 |
| Cefadroxil | 29 | $116 |
| Clindamycin Hcl | 13 | $115 |
| Cephalexin | 12 | $67 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $503 | $7,00518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 721 podiatrist providers in California.
Other podiatrist in Orange
- Shannon RushPleasanton$1.9M
- Babak BaravarianSanta Monica$1.1M
- Robert KleimanCalexico$913K
- Bruce LawrenceOceanside$810K
- David ArmstrongLos Angeles$695K
- Philip WrotslavskyPoway$269K
- Travis WestermeyerEncinitas$158K
- Adrienne EstesPomona$129K
- Ronald LiebermanEncinitas$109K
- Matthew DoyleMountain View$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.